Farallon Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-2,350,000
| Closed | -$11.4M | – | 134 |
|
|
2020
Q1 | $11.4M | Hold |
2,350,000
| – | – | 0.1% | 77 |
|
|
2019
Q4 | $25M | Buy |
2,350,000
+50,000
| +2% | +$496K | 0.17% | 76 |
|
|
2019
Q3 | $23.9M | Buy |
2,300,000
+800,000
| +53% | +$10.5M | 0.18% | 69 |
|
|
2019
Q2 | $23M | Sell |
1,500,000
-500,000
| -25% | -$7.23M | 0.15% | 73 |
|
|
2019
Q1 | $25.7M | Buy |
+2,000,000
| New | +$22.6M | 0.19% | 65 |
|
|
2017
Q4 | – | Sell |
-1,187,500
| Closed | -$13.2M | – | 93 |
|
|
2017
Q3 | $13.2M | Buy |
1,187,500
+30,000
| +3% | +$282K | 0.12% | 66 |
|
|
2017
Q2 | $10.6M | Sell |
1,157,500
-10,000
| -0.9% | -$83.4K | 0.11% | 65 |
|
|
2017
Q1 | $9.98M | Buy |
1,167,500
+910,000
| +353% | +$8.29M | 0.11% | 62 |
|
|
2016
Q4 | $2.75M | Buy |
+257,500
| New | +$3.11M | 0.03% | 66 |
|
|
2015
Q4 | – | Sell |
-676,162
| Closed | -$5.97M | – | 82 |
|
|
2015
Q3 | $5.97M | Buy |
676,162
+3,600
| +0.5% | +$37.8K | 0.08% | 68 |
|
|
2015
Q2 | $7.92M | Hold |
672,562
| – | – | 0.11% | 71 |
|
|
2015
Q1 | $9.73M | Buy |
672,562
+577,562
| +608% | +$8.84M | 0.14% | 69 |
|
|
2014
Q4 | $1.62M | Hold |
95,000
| – | – | 0.02% | 83 |
|
|
2014
Q3 | $1.18M | Hold |
95,000
| – | – | 0.02% | 80 |
|
|
2014
Q2 | $1.39M | Hold |
95,000
| – | – | 0.02% | 92 |
|
|
2014
Q1 | $1.93M | Hold |
95,000
| – | – | 0.04% | 76 |
|
|
2013
Q4 | $1.86M | Buy |
95,000
+36,000
| +61% | +$961K | 0.04% | 73 |
|
|
2013
Q3 | $2.67M | Sell |
59,000
-76,000
| -56% | -$2.48M | 0.05% | 73 |
|
|
2013
Q2 | $3.22M | Buy |
+135,000
| New | +$2.15M | 0.06% | 73 |
|
Farallon Capital Management's STML Position: Q2 2020 in Review
Farallon Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 2,350,000 shares — an estimated $11.4M sold.
Farallon Capital Management first reported a position in STML in Q2 2013 and held it in 19 quarters. The position peaked at $25.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Farallon Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Farallon Capital Management sold 2,350,000 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $11.4M.
- Farallon Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Farallon Capital Management's Stemline Therapeutics, Inc. position peaked at $25.7M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.